Larimar Therapeutics stock plunges after anaphylaxis cases in FA study
NegativeFinancial Markets

Larimar Therapeutics is facing a significant setback as its stock price plummets following reports of anaphylaxis cases in a recent Friedreich's Ataxia (FA) study. This news is concerning not only for investors but also for patients relying on the company's treatments, highlighting the risks involved in clinical trials and the potential impact on future research and development.
— Curated by the World Pulse Now AI Editorial System